It combines the effects of GLP-1 agonism with those of GIP, potentially offering additional benefits: - Enhanced insulin secretion and sensitivity - Greater appetite suppression - Improved lipid metabolism - Potential direct effects on adipose tissue[1] This dual action may explain why tirzepatide has shown superior efficacy in clinical trials, demonstrating greater reductions in HbA1c levels and body weight compared to existing therapies, including semaglutide[4]
Balancing blood sugar in people with insulin resistance
CoQ10 Supports Cellular Energy Production and Cardiovascular Function*
Hopefully, these potential adverse effects observed in animal studies will be addressed in clinical trials of these new, higher-dose oral GLP-1 drugs using SNAC before their widespread introduction
However, GIP receptor antagonism has not, so far, resulted in higher or lower circulating levels of GIP (46, 75, 87)
Sometimes, its as simple as giving your body what it needs directly, efficiently, and consistently. Click here for more information on Next Health